150 related articles for article (PubMed ID: 31184597)
1. β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion.
Barella LF; Rossi M; Zhu L; Cui Y; Mei FC; Cheng X; Chen W; Gurevich VV; Wess J
J Clin Invest; 2019 Jun; 129(9):3732-3737. PubMed ID: 31184597
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of skeletal muscle-specific deletion of beta-arrestin-1 and -2 in mice.
Meister J; Bone DBJ; Godlewski G; Liu Z; Lee RJ; Vishnivetskiy SA; Gurevich VV; Springer D; Kunos G; Wess J
PLoS Genet; 2019 Oct; 15(10):e1008424. PubMed ID: 31622341
[TBL] [Abstract][Full Text] [Related]
3. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
Zhang CL; Katoh M; Shibasaki T; Minami K; Sunaga Y; Takahashi H; Yokoi N; Iwasaki M; Miki T; Seino S
Science; 2009 Jul; 325(5940):607-10. PubMed ID: 19644119
[TBL] [Abstract][Full Text] [Related]
4. Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs.
Tsalkova T; Gribenko AV; Cheng X
Assay Drug Dev Technol; 2011 Feb; 9(1):88-91. PubMed ID: 21133673
[TBL] [Abstract][Full Text] [Related]
5. Sulphonylurea receptor-1, sulphonylureas and amplification of insulin secretion by Epac activation in β cells.
Nenquin M; Henquin JC
Diabetes Obes Metab; 2016 Jul; 18(7):698-701. PubMed ID: 26584950
[TBL] [Abstract][Full Text] [Related]
6. β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions.
Zhu L; Almaça J; Dadi PK; Hong H; Sakamoto W; Rossi M; Lee RJ; Vierra NC; Lu H; Cui Y; McMillin SM; Perry NA; Gurevich VV; Lee A; Kuo B; Leapman RD; Matschinsky FM; Doliba NM; Urs NM; Caron MG; Jacobson DA; Caicedo A; Wess J
Nat Commun; 2017 Feb; 8():14295. PubMed ID: 28145434
[TBL] [Abstract][Full Text] [Related]
7. Beneficial metabolic role of β-arrestin-1 expressed by AgRP neurons.
Pydi SP; Cui Z; He Z; Barella LF; Pham J; Cui Y; Oberlin DJ; Egritag HE; Urs N; Gavrilova O; Schwartz GJ; Buettner C; Williams KW; Wess J
Sci Adv; 2020 Jun; 6(23):eaaz1341. PubMed ID: 32537493
[TBL] [Abstract][Full Text] [Related]
8. β-Arrestin-1 is required for adaptive β-cell mass expansion during obesity.
Barella LF; Rossi M; Pydi SP; Meister J; Jain S; Cui Y; Gavrilova O; Fulgenzi G; Tessarollo L; Wess J
Nat Commun; 2021 Jun; 12(1):3385. PubMed ID: 34099679
[TBL] [Abstract][Full Text] [Related]
9. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
Remedi MS; Nichols CG
PLoS Med; 2008 Oct; 5(10):e206. PubMed ID: 18959471
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between cAMP signalling and sulfonylurea in insulin secretion.
Shibasaki T; Takahashi T; Takahashi H; Seino S
Diabetes Obes Metab; 2014 Sep; 16 Suppl 1():118-25. PubMed ID: 25200305
[TBL] [Abstract][Full Text] [Related]
11. Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S; Takahashi H; Takahashi T; Shibasaki T
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
[TBL] [Abstract][Full Text] [Related]
12. β-arrestin-1 suppresses myogenic reprogramming of brown fat to maintain euglycemia.
Pydi SP; Jain S; Barella LF; Zhu L; Sakamoto W; Meister J; Wang L; Lu H; Cui Y; Gavrilova O; Wess J
Sci Adv; 2020 Jun; 6(23):eaba1733. PubMed ID: 32548266
[TBL] [Abstract][Full Text] [Related]
13. Insulin stimulus-secretion coupling is triggered by a novel thiazolidinedione/sulfonylurea hybrid in rat pancreatic islets.
Mendes CP; Postal BG; Oliveira GTC; Castro AJG; Frederico MJS; Moraes ALL; Neuenfeldt PD; Nunes RJ; Menegaz D; Silva FRMB
J Cell Physiol; 2018 Jan; 234(1):509-520. PubMed ID: 29968920
[TBL] [Abstract][Full Text] [Related]
14. A red-shifted photochromic sulfonylurea for the remote control of pancreatic beta cell function.
Broichhagen J; Frank JA; Johnston NR; Mitchell RK; Šmid K; Marchetti P; Bugliani M; Rutter GA; Trauner D; Hodson DJ
Chem Commun (Camb); 2015 Apr; 51(27):6018-21. PubMed ID: 25744824
[TBL] [Abstract][Full Text] [Related]
15. Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
Magnusson NE; Dyrskjøt L; Grimm D; Wehland M; Pietsch J; Rungby J
Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):254-61. PubMed ID: 22642398
[TBL] [Abstract][Full Text] [Related]
16. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.
Gregorio F; Ambrosi F; Cristallini S; Pedetti M; Filipponi P; Santeusanio F
Diabetes Res Clin Pract; 1992 Dec; 18(3):197-206. PubMed ID: 1289021
[TBL] [Abstract][Full Text] [Related]
17. Epac2: a sulfonylurea receptor?
Rehmann H
Biochem Soc Trans; 2012 Feb; 40(1):6-10. PubMed ID: 22260657
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
Loubatières A; Ribes G; Mariani MM; Alric R
Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
[No Abstract] [Full Text] [Related]
19. Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C.
Tian YA; Johnson G; Ashcroft SJ
Diabetes; 1998 Nov; 47(11):1722-6. PubMed ID: 9792541
[TBL] [Abstract][Full Text] [Related]
20. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion.
Takahashi H; Shibasaki T; Park JH; Hidaka S; Takahashi T; Ono A; Song DK; Seino S
Diabetes; 2015 Apr; 64(4):1262-72. PubMed ID: 25315008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
